Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988125245> ?p ?o ?g. }
- W2988125245 endingPage "1066" @default.
- W2988125245 startingPage "1066" @default.
- W2988125245 abstract "Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal hematologic disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ impairment. The incidence of iTTP is higher among African-Americans (AA), however, differences in presentation and outcomes have not been fully investigated. In a multi-center cohort of patients with iTTP from the United States Thrombotic Microangiopathy (USTMA) Consortium, we tested the hypothesis that AA race is an independent predictor of poor outcomes including iTTP related mortality and relapse. Methods: We queried data from the USTMA iTTP registry, which currently includes data from 785 individual patients from 15 institutions across the United States. Data from at least one iTTP episode are available for 734 patients. The cohort is 35.1% (N = 272) White, 58.7% (N = 455) African American, 0.4% (N=3) Asian, 1.8% (N=14) Hispanic, and 4.0 % (N=31) other/unknown race. We restricted our analyses to AA and White participants because of small numbers in the other groups. We compared presenting features and treatments using the chi-squared test and t-test for categorical and continuous variables, respectively. A relapse was defined as a recurrent iTTP episode occurring at least 30 days after last therapeutic plasma exchange. To evaluate relapse-free survival, we included only patients enrolled in the registry at their first TTP episode (144 White and 246 AA) since patients presenting with a relapse as their index episode are already confirmed to have relapsing iTTP. Kaplan Meier analysis was used to compare relapse-free survival in White and AA patients, and a Cox regression model was developed to evaluate the independent effect of race on relapse, adjusting for potential confounders including age, sex, and the use of rituximab. Results: Demographics and presenting features of 390 individuals (144 White and 246 AA) presenting with a first episode of iTTP are shown in Table 1. Presenting symptoms including fever, confusion, seizure, memory deficits, stupor, headache, stroke, chest pain, abdominal pain, fatigue, and dark urine were similar between Whites and AA except for petechiae, which were more frequently documented in Whites (28.8% vs 17.7%, p=0.011). Presenting laboratory studies were also comparable though AA had a higher rate of elevated serum troponin (50.6% vs 32.5%, p=0.003), lower hemoglobin level (8.27 ± 0.13 vs 8.81 ± 0.19, p=0.0176) and platelet count (20.3 ± 1.2 vs 26.2 ± 3.2, p=0.0432). In addition to therapeutic plasma exchange and corticosteroids, rituximab was administered to 23.7% of White patients and 22.7% of AA during their first iTTP episode (P=0.815). Median time to platelet count recovery (days of daily plasma exchange until normal platelet count for two consecutive days) was shorter in AA compared with White patients [5 (IQR 4, 10) vs. 8 (IQR 5, 14), log rank P = 0.004]. AA race remained a significant predictor of the shorter time to platelet count recovery [HR 1.44 (95% CI 1.12, 1.85), P=0.004] after adjusting for rituximab therapy [HR 0.60 (95% CI 0.0.46, 0.80), P<0.001], female sex [HR 0.95 (95% CI 0.73, 1.22), P=0.669], age [HR 0.99 (95% CI 0.99, 1.01), P=0.682], platelet count [HR 1.00 (95% CI 0.99, 1.04), P=0.820] and LDH at presentation [HR 1.00 (95% CI 1.00, 1.00), P=0.525]. Death during the first episode occurred in 8.9% of White patients and 5.5% of AA patients (P=0.206). Relapse-free survival after the first episode of iTTP was lower in AA than White patients (Figure 1). AA race was associated with the reduced relapse free survival [HR 1.79 (95% CI 1.08, 2.98), P=0.024] in a Cox regression model adjusted for age [HR 1.00 (95% CI 0.98, 1.01), P=0.683], sex [HR 0.96 (95% CI 0.60, 1.54), P=0.867], and rituximab therapy [HR 0.93 (95% CI 0.55, 1.59), P=0.806]. Conclusion: African Americans with iTTP have a higher relapse rate and shorter relapse free survival after the first episode of the disease compared with Caucasian patients, which is independent of age, sex and rituximab therapy. Contrary to our hypothesis, acute outcomes of iTTP (time to platelet count recovery and mortality) were not worse in AA patients. The factors contributing to the higher relapse rate in AA with iTTP need to be further investigated. Our findings suggest that AA patients may also benefit from closer follow up. Disclosures Farland: Sanofi: Membership on an entity's Board of Directors or advisory committees. Metjian:Sanofi: Membership on an entity's Board of Directors or advisory committees. Raval:Bayer, Inc: Research Funding; Sanofi: Membership on an entity's Board of Directors or advisory committees. Liles:Shire: Other: PI on clinical trial Sickle cell ; Imara: Other: PI on Clinical trial- Sickle cell ; Novartis: Other: PI on clinical trial Sickle cell . Baumann Kreuziger:CSL Behring: Consultancy; Vaccine Injury Compensation Program: Consultancy. McCrae:Dova Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Pfizer Pharmaceutical: Membership on an entity's Board of Directors or advisory committees; Rigel Pharmaceutical: Membership on an entity's Board of Directors or advisory committees; Sanofi Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees. Zheng:Alexion: Speakers Bureau; Ablynx/Sanofi: Consultancy, Speakers Bureau; Clotsolution: Other: Co-Founder; Shire/Takeda: Research Funding. Cataland:Alexion: Consultancy, Research Funding; Ablynx/Sanofi: Consultancy, Research Funding. Chaturvedi:Shire/Takeda: Research Funding; Sanofi: Consultancy; Alexion: Consultancy." @default.
- W2988125245 created "2019-11-22" @default.
- W2988125245 creator A5005704032 @default.
- W2988125245 creator A5006839060 @default.
- W2988125245 creator A5016600458 @default.
- W2988125245 creator A5018928883 @default.
- W2988125245 creator A5019404931 @default.
- W2988125245 creator A5020318774 @default.
- W2988125245 creator A5021125884 @default.
- W2988125245 creator A5025304488 @default.
- W2988125245 creator A5029554853 @default.
- W2988125245 creator A5029802364 @default.
- W2988125245 creator A5031686663 @default.
- W2988125245 creator A5034738723 @default.
- W2988125245 creator A5035031332 @default.
- W2988125245 creator A5040255163 @default.
- W2988125245 creator A5044794766 @default.
- W2988125245 creator A5046695529 @default.
- W2988125245 creator A5046710365 @default.
- W2988125245 creator A5047512989 @default.
- W2988125245 creator A5047662648 @default.
- W2988125245 creator A5052258400 @default.
- W2988125245 creator A5053638396 @default.
- W2988125245 creator A5057823499 @default.
- W2988125245 creator A5059921628 @default.
- W2988125245 creator A5062068085 @default.
- W2988125245 creator A5065046293 @default.
- W2988125245 creator A5069454266 @default.
- W2988125245 creator A5070606803 @default.
- W2988125245 creator A5076923577 @default.
- W2988125245 creator A5079499149 @default.
- W2988125245 creator A5089955948 @default.
- W2988125245 date "2019-11-13" @default.
- W2988125245 modified "2023-10-01" @default.
- W2988125245 title "African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura" @default.
- W2988125245 doi "https://doi.org/10.1182/blood-2019-131064" @default.
- W2988125245 hasPublicationYear "2019" @default.
- W2988125245 type Work @default.
- W2988125245 sameAs 2988125245 @default.
- W2988125245 citedByCount "2" @default.
- W2988125245 countsByYear W29881252452023 @default.
- W2988125245 crossrefType "journal-article" @default.
- W2988125245 hasAuthorship W2988125245A5005704032 @default.
- W2988125245 hasAuthorship W2988125245A5006839060 @default.
- W2988125245 hasAuthorship W2988125245A5016600458 @default.
- W2988125245 hasAuthorship W2988125245A5018928883 @default.
- W2988125245 hasAuthorship W2988125245A5019404931 @default.
- W2988125245 hasAuthorship W2988125245A5020318774 @default.
- W2988125245 hasAuthorship W2988125245A5021125884 @default.
- W2988125245 hasAuthorship W2988125245A5025304488 @default.
- W2988125245 hasAuthorship W2988125245A5029554853 @default.
- W2988125245 hasAuthorship W2988125245A5029802364 @default.
- W2988125245 hasAuthorship W2988125245A5031686663 @default.
- W2988125245 hasAuthorship W2988125245A5034738723 @default.
- W2988125245 hasAuthorship W2988125245A5035031332 @default.
- W2988125245 hasAuthorship W2988125245A5040255163 @default.
- W2988125245 hasAuthorship W2988125245A5044794766 @default.
- W2988125245 hasAuthorship W2988125245A5046695529 @default.
- W2988125245 hasAuthorship W2988125245A5046710365 @default.
- W2988125245 hasAuthorship W2988125245A5047512989 @default.
- W2988125245 hasAuthorship W2988125245A5047662648 @default.
- W2988125245 hasAuthorship W2988125245A5052258400 @default.
- W2988125245 hasAuthorship W2988125245A5053638396 @default.
- W2988125245 hasAuthorship W2988125245A5057823499 @default.
- W2988125245 hasAuthorship W2988125245A5059921628 @default.
- W2988125245 hasAuthorship W2988125245A5062068085 @default.
- W2988125245 hasAuthorship W2988125245A5065046293 @default.
- W2988125245 hasAuthorship W2988125245A5069454266 @default.
- W2988125245 hasAuthorship W2988125245A5070606803 @default.
- W2988125245 hasAuthorship W2988125245A5076923577 @default.
- W2988125245 hasAuthorship W2988125245A5079499149 @default.
- W2988125245 hasAuthorship W2988125245A5089955948 @default.
- W2988125245 hasConcept C126322002 @default.
- W2988125245 hasConcept C187212893 @default.
- W2988125245 hasConcept C2777878052 @default.
- W2988125245 hasConcept C2778585876 @default.
- W2988125245 hasConcept C2779134260 @default.
- W2988125245 hasConcept C2781127562 @default.
- W2988125245 hasConcept C71924100 @default.
- W2988125245 hasConcept C72563966 @default.
- W2988125245 hasConcept C89560881 @default.
- W2988125245 hasConcept C90924648 @default.
- W2988125245 hasConceptScore W2988125245C126322002 @default.
- W2988125245 hasConceptScore W2988125245C187212893 @default.
- W2988125245 hasConceptScore W2988125245C2777878052 @default.
- W2988125245 hasConceptScore W2988125245C2778585876 @default.
- W2988125245 hasConceptScore W2988125245C2779134260 @default.
- W2988125245 hasConceptScore W2988125245C2781127562 @default.
- W2988125245 hasConceptScore W2988125245C71924100 @default.
- W2988125245 hasConceptScore W2988125245C72563966 @default.
- W2988125245 hasConceptScore W2988125245C89560881 @default.
- W2988125245 hasConceptScore W2988125245C90924648 @default.
- W2988125245 hasIssue "Supplement_1" @default.
- W2988125245 hasLocation W29881252451 @default.
- W2988125245 hasOpenAccess W2988125245 @default.
- W2988125245 hasPrimaryLocation W29881252451 @default.
- W2988125245 hasRelatedWork W1969018345 @default.
- W2988125245 hasRelatedWork W2073597868 @default.